Organic cation transporter 2 for predicting cisplatin-based neoadjuvant chemotherapy response in gastric cancer.
Some studies have shown the usability of neoadjuvant chemotherapy (NAC) in gastric cancer (GC). Nevertheless there are a few predictive markers of the effectiveness of NAC in GC. The aim of this study is to assess the predictive impact of organic cation transporter 2 (OCT2) expression on response to neoadjuvant chemotherapy (NAC) in gastric cancer. We retrospectively assessed 66 patients with advanced gastric cancer received NAC with S-1/cisplatin or paclitaxel/cisplatin. Expression levels of OCT2 were assessed by immunohistochemistry in pre-chemotherapy biopsies and correlated with clinicopathologic parameters including pathologic response. High expression level of OCT2 (OCT2(high)) was significantly associated with intestinal type according to Laurén classification (P = 0.03) and low histologic grade (P = 0.03). In univariate analysis of the entire cohort, no variables showed any significant association with a response, although intestinal type (P = 0.09), low histologic grade (P = 0.09), and OCT2(high) (P = 0.07) tended to be more frequent in responders compared with non-responders. When the two treatment groups were separately assessed in the univariate analysis, a significantly higher rate of OCT2(high) was observed in responders compared with non-responders in the S-1/cisplatin group (P = 0.001). In addition, multivariate analysis identified OCT2(high) as the sole independent predictor of response (P = 0.04). However, in the paclitaxel/cisplatin group, no variables were associated with response. Taken together, our results suggest that OCT2(high) may represent a potential predictor of response to NAC with S-1/cisplatin in gastric cancer.
Department of Medical Biophysics, Laboratory of Pathology, Kobe University Graduate School of Health Sciences 7-10-2 Tomogaoka, Suma, Kobe, Hyogo 654-0142, Japan.
Ayano
A
Naka
Department of Medical Biophysics, Laboratory of Pathology, Kobe University Graduate School of Health Sciences 7-10-2 Tomogaoka, Suma, Kobe, Hyogo 654-0142, Japan.
Risa
R
Takeda
Department of Medical Biophysics, Laboratory of Pathology, Kobe University Graduate School of Health Sciences 7-10-2 Tomogaoka, Suma, Kobe, Hyogo 654-0142, Japan.
Michiko
M
Shintani
Department of Pathology, Kanagawa Prefectural Ashigarakami Hospital 866-1 Matsudasoryo, Matsuda-cho, Ashigarakami-gun, Kanagawa 258-0003, Japan.
Naoki
N
Ogane
Department of Pathology, Kanagawa Prefectural Ashigarakami Hospital 866-1 Matsudasoryo, Matsuda-cho, Ashigarakami-gun, Kanagawa 258-0003, Japan ; Department of Pathology, Kanagawa Cancer Center Hospital 1-1-2 Nakao, Asahi-ku 241-0815, Japan.
Yoichi
Y
Kameda
Department of Gastrointestinal Surgery, Kanagawa Cancer Center Hospital 1-1-2 Nakao, Asahi-ku, Yokohama 241-0815, Japan.
Toru
T
Aoyama
Department of Gastrointestinal Surgery, Kanagawa Cancer Center Hospital 1-1-2 Nakao, Asahi-ku, Yokohama 241-0815, Japan.
Takaki
T
Yoshikawa
Department of Medical Biophysics, Laboratory of Pathology, Kobe University Graduate School of Health Sciences 7-10-2 Tomogaoka, Suma, Kobe, Hyogo 654-0142, Japan.
Shingo
S
Kamoshida
Organic cation transporter 2; S-1 plus cisplatin; gastric cancer; immunohistochemistry; neoadjuvant chemotherapy